<DOC>
	<DOCNO>NCT01320293</DOCNO>
	<brief_summary>Severe psoriasis demonstrate associate decreased endothelial function increase risk future coronary event . Although systemic therapy immunomodulatory agent show improve psoriatic symptom , effect systemic inflammation endothelial function unknown . In study want ass cardiovascular risk factor , endothelial dysfunction inflammatory marker treatment moderate severe psoriasis FDA-approved biologic agent , adalimumab ( Humira ) .</brief_summary>
	<brief_title>Cardiovascular Effects Psoriasis Patients Treated With Adalimumab .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form . Must male female age 1855 year time consent . Must able adhere study visit schedule protocol requirement Have chronic plaque psoriasis 6 month PASI score 12 great Baseline . Females childbearing potential ( FCBP ) â€¡ must negative urine pregnancy test screening ( Visit 1 ) . Negative PPD Screening 3 month earlier . Have use biologic treatment psoriasis past 12 month . Inability provide voluntary consent Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant , try become pregnant breastfeed Prior diagnosis coronary artery disease ( CAD ) heart disease . Systemic fungal infection History past active mycobacterial infection specie ( include Mycobacterium tuberculosis ) . Latent Mycobacterium tuberculosis infection indicate positive ( 15mm induration ) Purified Protein Derivative [ PPD ] skin test . Subjects positive PPD skin test document completion treatment latent TB eligible . Subjects positive PPD skin test treat documentation completion treatment ineligible . History recurrent bacterial infection ( least 3 major infection result hospitalization and/or require intravenous antibiotic treatment within past 2 year ) Clinically significant abnormality chest xray ( CXR ) screening . Chest xrays perform within 3 month prior start study drug acceptable . Use investigational medication within 4 week prior start study drug 5 pharmacokinetic/pharmacodynamic halflives ( whichever longer ) History Human Immunodeficiency Virus ( HIV ) infection Hepatitis C Positive Hepatitis B Surface antigen screen Malignancy history malignancy ( except treat [ ie , cure ] basalcell skin carcinoma &gt; 3 year prior screen ) History demyelinate disorder multiple sclerosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Moderate Severe Chronic plaque type psoriasis</keyword>
</DOC>